Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 12, 2009, Pages 827-832

  Muslimani, Alaa A ^a   Spiro, Timothy P ^b   Chaudhry, Asif A ^b   Taylor, Harris C ^c   Jaiyesimi, Ishmael ^a   Daw, Hamed A ^b  

^a William Beaumont Cancer Center   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Monoclonal gammopathy of undetermined significance (MGUS); Plasma cell dyscrasias; Venous thromboembolism

Indexed keywords

M PROTEIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; NEOPLASM; PLASMA CELL; RISK FACTOR; VENOUS THROMBOEMBOLISM;

DISEASE PROGRESSION; HUMANS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

EID: 76149105791     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978;64:814-826.
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
3. Axelsson U. A 20-year follow-up study of 64 subjects with M-components. Acta Med Scand. 1986;219:519-522.
4. Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood. 1972;40:719-724.
5. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362-1369.
6. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
7. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102:3759-3764.
8. Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P. Cancer and venous thromboembolism. Semin Thromb Hemost. 2006;32:694-699.
9. Monreal M, Casals A, Boix J, Olazabal A, Montserrat E, Mundo MR. Occult cancer in patients with acute pulmonary embolism. A prospective study. Chest. 1993;103:816-819.
10. Goldberg RJ, Seneff M, Gore JM, et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med. 1987;147:251-253.
11. Prandoni P, Lensing AW, Büller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128-1133.
12. Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med. 1996;125:785-793.
13. Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res. 2001;102:V187-V194.
14. Piccioli A, Lensing AW, Prins MH, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2004;2:884-889.
15. Oudega R, Moons KG, Karel Nieuwenhuis H, van Nierop FL, Hoes AW. Deep vein thrombosis in primary care: possible malignancy? Br J Gen Pract. 2006;56:693-696.
16. Ronsdorf A, Perruchoud AP, Schoenenberger RA. Search for occult malignancy in patients with deep venous thrombosis. Results of a retrospective cohort study. Swiss Med Wkly. 2003;133:567-574.
17. Monreal M, Trujillo-Santos J. Screening for occult cancer in patients with acute venous thromboembolism. Curr Opin Pulm Med. 2007;13:368-371.
18. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169-1173.
19. Nand S, Fisher SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol. 1987;5:1998-2003.
20. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812-817.
21. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol. 2009;145:151-163.
22. Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. Clin Lymphoma Myeloma. 2007;7:462-466.
23. Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol. 2004;15:1490-1494.
24. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004;101:558-566.
25. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis following monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112:3582-3586.
26. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
27. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8:2210-2216.
28. Kerr R. Interleukin 6 and hemostasis. Br J Haematol. 2001;115:3-12.
29. Baldini L, Guffanti A, Cesana BM, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood. 1996;87:912-918.
30. Suwa T, Hogg JC, English D, Van Eeden SF. Interleukin-6 induces margination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol. 2000;279:H2954-H2960.
31. Wong GG, Witek-Giannotti JS, Temple PA, et al. Stimulation of murine hemopoetic colony formation by human IL-6. J Immunol. 1988;140:3040-3044.
32. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245-270.
33. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625-1634.
34. Rosiñol L, Cibeira MT, Montoto S, et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc. 2007;82:428-434.
35. Rajkumar SV, Kyle RA, Therneau TM, et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol. 2004;127:308-310.
36. Kwaan H, Bongu A. The hyperviscosity syndromes. Semin Thromb Hemost. 1999;25:199-208.
37. Gabriel DA, Smith LA, Folds JD, Davis L, Cancelosi SE. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med. 1983;101:545-552.
38. Carr ME, Zebkert SL. Abnormal clot reaction, altered fibrin structure, and normal platelet function in multiple myeloma. Am J Physiol. 1994;266:1195-1201.